论文部分内容阅读
目的探讨舒洛地特对移植肾肾病蛋白尿的疗效。方法 28例移植肾肾病伴蛋白尿的患者,分为治疗组14例(舒洛地特软胶囊500LSU/d,疗程3个月)和对照组14例(不使用舒洛地特),观察2组治疗前后24h尿蛋白定量、尿白蛋白排泄率(UAER)、纤维蛋白原(Fbg)、PT、TT、APTT、血肌酐、尿素氮等指标。结果与治疗前相比,两组治疗后BUN、Cr、UA无明显变化(P>0.05)。治疗组24 h尿蛋白定量、尿白蛋白排泄率较治疗前明显下降(P<0.05),治疗组与对照组相比有显著性差异(P<0.05),纤维蛋白原(Fbg)较治疗前下降,差异有显著性(P<0.05);PT、TT、APTT均较治疗前延长,差异有显著性(P<0.05)。结论舒洛地特能有效减少尿蛋白、抗凝从而起到保护移植肾肾功能的作用,无明显不良反应,使用安全有效。
Objective To investigate the curative effect of sulodentiride on proteinuria in renal transplant recipients. Methods Twenty-eight patients with renal allograft nephropathy with proteinuria were divided into treatment group (n = 14) (Salbutamter soft capsule 500LSU / d for 3 months) and control group (n = 14) Urinary protein excretion, urinary albumin excretion rate (UAER), fibrinogen (Fbg), PT, TT, APTT, serum creatinine and urea nitrogen were measured 24h before and after treatment. Results Compared with those before treatment, BUN, Cr and UA did not change significantly in both groups after treatment (P> 0.05). The urinary protein excretion and urinary albumin excretion rate in treatment group decreased significantly compared with those before treatment (P <0.05), there was significant difference between treatment group and control group (P <0.05), fibrinogen (Fbg) (P <0.05). The PT, TT, APTT were longer than before treatment, the difference was significant (P <0.05). Conclusion Shuluotedi can effectively reduce urinary protein, anticoagulation and thus play a protective renal graft function, no obvious adverse reactions, the use of safe and effective.